AdAlta Bilan de santé

Santé financière contrôle des critères 3/6

AdAlta possède un total de capitaux propres de A$2.0M et une dette totale de A$2.6M, ce qui porte son ratio d'endettement à 128.3%. Son actif total et son passif total sont A$5.6M et de A$3.5M.

Informations clés

128.3%

Ratio d'endettement

AU$2.61m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$3.13m
Fonds propres	AU$2.03m
Total du passif	AU$3.54m
Total des actifs	AU$5.57m

Mises à jour récentes de la santé financière

Recent updates

Is AdAlta (ASX:1AD) A Risky Investment?

Oct 11

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Jun 11

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Feb 26

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 1AD ( A$5.3M ) dépassent ses passifs à court terme ( A$2.2M ).

Passif à long terme: Les actifs à court terme de 1AD ( A$5.3M ) dépassent ses passifs à long terme ( A$1.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 1AD dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 1AD est passé de 0% à 128.3% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 1AD dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 1AD dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 0 % chaque année

AdAlta Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Is AdAlta (ASX:1AD) A Risky Investment?

Is AdAlta (ASX:1AD) Using Debt Sensibly?

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Recent updates

AdAlta Limited Appoints Kevin Lynch as Consultant Chief Medical Officer of AdCella

AdAlta Limited, Annual General Meeting, Nov 20, 2024

Is AdAlta (ASX:1AD) A Risky Investment?

New major risk - Shareholder dilution

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

New major risk - Financial position

AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.

AdAlta Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Less than half of directors are independent

AdAlta Limited Provides an Update on Its Lead Program, AD-214

AdAlta Limited, Annual General Meeting, Nov 22, 2022

AdAlta Limited, Annual General Meeting, Nov 22, 2022

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)

AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology Studies

Price target increased to AU$0.27

Less than half of directors are independent

Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.

Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary Fibrosis

AdAlta Limited Announces Phase I HV Extension to Explore Encouraging Results

AdAlta Limited Announces the Extension of its Collaboration with GE Healthcare

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.

Full year earnings released - AU$0.037 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines